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Background: Little is known about trends in the utilization or complication rates of transbron-
chial lung biopsy, particularly in community hospitals.
Methods: We used the Healthcare Cost and Utilization Project Florida State Inpatient and State
Ambulatory Surgical Databases to assess trends in transbronchial lung biopsy utilization in
adults from 2000 to 2009. We subsequently calculated population based estimates of compli-
cations associated with transbronchial lung biopsy (iatrogenic pneumothorax and procedure-
related hemorrhage) and identified characteristics associated with complications.
Results: From 2000 to 2009, the age-adjusted rate of transbronchial biopsies per 100,000
adults in Florida decreased by 25% from 74 to 55 (p < 0.0001), despite stability in the overall
utilization of bronchoscopy. Analysis of 82,059 procedures revealed that complications associ-
ated with transbronchial biopsy were uncommon and stable over the study period, with 0.97%
(95% CI 0.94e1.01%) of procedures complicated by pneumothorax, 0.55% (95% CI 0.52e0.58%)
by pneumothorax requiring chest tube placement, and 0.58% (95% CI 0.55e0.61%) by
procedure-related hemorrhage. Patients with COPD (OR 1.51, 95% CI 1.31e1.75) and women
(OR 1.32, 95% CI 1.15e1.52) were at increased risk for pneumothorax, while renal failure
(OR 2.85, 95% CI 2.10e3.87), cirrhosis (OR 2.31, 95% CI 1.18e4.52), older age (OR 1.17, 95%
CI 1.09e1.25) and female sex (OR 1.40, 95% CI 1.17e1.68) were associated with higher risk
of procedure-related hemorrhage.
Conclusions: Utilization of transbronchial lung biopsy is decreasing relative to the overall use
of bronchoscopy. Nevertheless, it remains a safe procedure with low risk of complications.
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According to professional guidelines, bronchoscopy with
transbronchial lung biopsy may be considered as a less
invasive alternative to surgical biopsy for the evaluation of
pulmonary nodules and parenchymal lung disease.1 Little is
known, however, about how commonly and for which
patients this procedure is currently used. In particular, it is
not known how the introduction and proliferation of other
less invasive methods of obtaining lung specimens have
affected utilization of transbronchial lung biopsy.
In light of reported mortality rates as high as 1e2 per
1000 patients undergoing transbronchial biopsy,2,3 concerns
for complications related to transbronchial biopsy,
including pneumothorax and procedure-related hemor-
rhage, may influence the use of this procedure. There are
only limited data about which characteristics place indi-
viduals at increased risk for complications following trans-
bronchial lung biopsy.
We sought to address this gap in the literature by using
the Florida State Inpatient Databases and State Ambulatory
Surgery Databases from 2000 to 2009 to examine trends in
the utilization of transbronchial lung biopsy and to calcu-
late population-based estimates of complications associ-
ated with this procedure.Methods
Data source
We used the Healthcare Cost and Utilization Project Agency
for Healthcare Research and Quality Florida State Inpatient
Databases and State Ambulatory Surgery Databases from
2000 to 2009. The State Inpatient Database includes
discharge data from approximately 93% of non-federal
acute care community hospitals in Florida.4 The State
Ambulatory Surgery Database includes data from all
ambulatory surgical centers in Florida that experience
more than 200 visits per quarter.5 Each record in the State
Inpatient Database contains multiple data elements
including patient demographic characteristics, and up to 31
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnoses and up to 31 ICD-
9-CM procedure codes. The State Ambulatory Surgical
Database contains similar demographic elements and up to
15 Current Procedural Terminology (CPT) codes and 5 ICD-9-
CM diagnosis codes.
Study population
We identified adults (age  18) who had undergone bron-
choscopy with transbronchial biopsy in Florida from 2000 to
2009 by the presence of the code for transbronchial lung
biopsy (ICD-9-CM 33.27; CPT 31628) on the discharge
record. For comparison we also identified patients who had
undergone other diagnostic pulmonary procedures
including any bronchoscopy, bronchoscopy with other
bronchoscopic biopsy (bronchoalveolar lavage, bronchial
washing, bronchial brushing or endobronchial biopsy), or
other lung biopsy procedures (mediastinoscopy, open lungbiopsy, transthoracic needle biopsy). In addition to basic
demographic characteristics, we identified medical condi-
tions associated with transbronchial lung biopsy, which
were not considered mutually exclusive, by the presence of
select codes in any of the diagnosis code fields.
Outcomes
Our main outcome was the risk of complications associated
with transbronchial biopsy. For our analysis of risk of
complications associated with transbronchial biopsy, we
excluded patients who had undergone other common
procedures within the chest cavity during the same visit
(e.g., central line placement, thoracentesis). We identified
pneumothorax by the presence of the ICD-9-CM diagnosis
code for “iatrogenic pneumothorax” (ICD-9-CM 512.1). The
outcome of pneumothorax requiring chest tube placement
was defined as the presence of codes for both iatrogenic
pneumothorax and chest tube placement during a single
visit in patients without co-existing pleural effusion. We
identified procedure related hemorrhage by the presence
of the ICD-9-CM diagnosis code for hemorrhage compli-
cating a procedure (ICD-9-CM 998.11). Additional details on
the coding strategy can be found in Appendix 1.
Statistical analysis
The annual rate of transbronchial lung biopsy per 100,000
adults in Florida for each year from 2000 to 2009 was
calculated and age standardized to the US census distri-
bution from 2000.6,7 Age-adjusted rates of competing
procedures were calculated in the same manner. Annual
percent change (APC) in procedure utilization and
procedure-related complications were calculated using the
JoinPoint Regression Program, version 3.5.2 (Statistical
Research and Applications Branch, National Cancer
Institute).
We used logistic regression analysis to examine charac-
teristics associated with iatrogenic pneumothorax and
procedure-related hemorrhage. We used single-predictor
logistic regression to identify significant associations
between biopsy characteristics and complications. For the
multivariable models, covariates with p <0.2 were entered
into the model and remained via backward selection if p
<0.05, the predetermined level of significance. To account
for interactions among variables we examined interaction
terms. None of the interactions were significant in the
multivariable models.
We performed a series of sensitivity analyses to address
potential limitations of using administrative databases.
Across the study period, the maximum number of ICD-9-CM
codes and CPT codes recorded in the Florida databases was
not consistent, ranging from 10 to 31. The primary analysis
allows the maximum number of procedure and diagnosis
codes available for each year. To address the possibility
that changes in the number of codes falsely affected our
results over time, the analysis was repeated limiting the
number of ICD-9-CM and CPT codes to 10 per record across
all years. To address the possibility that a change in the
rate of transbronchial biopsy over time represents a change
in coding practice instead of a change in procedure
Table 1 Demographic characteristics of patients under-
going transbronchial biopsy in Florida in 2000 compared to
2009.
2000 2009
Age (mean, SD) 64.9 (14.7) 63.6 (14.3)
Female (%) 45.5 47.0
Race (%)
White 82.3 78.7
Black 10.4 11.2
Hispanic 5.8 6.6
Asian or Pacific islander 0.3 0.8
Native American 0.1 0.1
Transbronchial biopsy use and complications 1561utilization (i.e., a possible “crowding out” of minor
procedures from the discharge record if the number of
procedures per visit increased over time), we also analyzed
the combined frequency with which other bronchoscopic
biopsy procedures were coded during the study period. To
address the possibility that the code for iatrogenic pneu-
mothorax was too specific, we also analyzed risk of pneu-
mothorax using the non-specific “any pneumothorax” code
(ICD-9-CM 512). Unless specified, all analyses were per-
formed using the SAS version 9.1.3 statistical software
(Cary, NC). This study was reviewed and determined to be
exempt by the Boston University Medical Campus Institu-
tional Review Board.Other 1.0 2.6
Associated conditions (%)
Pulmonary nodule or malignancy 43.4 39.5
Unspecified pneumonia 16.0 19.3
Hemoptysis 9.3 8.0
Pulmonary eosinophilia 5.5 5.3
Pulmonary fibrosis 8.0 9.5
Lung transplant 2.0 11.1
HIV 5.0 2.5
Sarcoidosis 1.3 1.7Results
Utilization of transbronchial biopsy, bronchoscopy
and other lung biopsy procedures
From 2000 to 2009, the Florida State Inpatient Database
and State Ambulatory Surgery Databases contained data
from 48,553,802 adult patient visits, 99,533 of which
involved transbronchial lung biopsy (Fig. 1). Table 1 shows
characteristics of the study population. The age adjusted
annual rate of transbronchial biopsy decreased by 25% over
the 10-year study period (74 versus 55 procedures per
100,000 adults, APC 3.2%, p < 0.0001). Demographic
characteristics such as age, race and gender were similar
during the study period. The most common diagnosis codes
associated with transbronchial biopsy were related to
pulmonary nodules or lung cancer. While the frequency ofFigure 1 Studymost diagnosis codes associated with transbronchial biopsy
was consistent during the study period, the proportion of
transbronchial biopsies performed in the setting of lung
transplantation increased from 2.0% to 11.1%. The number
of lung transplant surgeries performed in Florida similarly
increased from 23 in 2000 to 125 in 2009 (0.19 versus 0.85
procedures per 100,000 adults).flow diagram.
Figure 3 Age-adjusted rates of utilization of lung biopsy
procedures in Florida from 2000 to 2009.
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zation of transbronchial lung biopsy, the age adjusted
overall utilization of bronchoscopy was unchanged (268
versus 275 procedures per 100,000 adults, APC 0.19%,
p Z 0.39). The combined age adjusted utilization of other
bronchoscopic biopsy techniques, however, increased
during this period (153 versus 195 procedures per 100,000
adults, APC 2.7%, p < 0.0001), see Fig. 2. The utilization of
mediastinoscopy (12 versus 12 procedures per 100,000
adults, APC 0.0%, p Z 0.99) and transthoracic needle lung
biopsy (54 versus 52 procedures per 100,000 adults, APC
0.0%, p Z 0.99) were unchanged. The rate of surgical lung
biopsy (combined total of open and thoracoscopic proce-
dures) decreased during the study period (12 versus 9.1
procedures per 100,000 adults, APC 3.6%, p Z 0.0003),
see Fig. 3.
Risk of complications
After excluding patients who had undergone additional
procedures during the encounter associated with risk for
the complications of interest, we calculated that 0.97%
(95% CI 0.94%e1.01%) of transbronchial lung biopsies were
complicated by iatrogenic pneumothorax, 0.55% (95% CI
0.52%e0.58%) by pneumothorax requiring chest tube
placement and 0.58% (95% CI 0.55%e0.61%) by procedure
related hemorrhage. Using a less specific definition of any
pneumothorax, the risks calculated were slightly higher at
1.45% (95% CI 1.41%e1.49%). Overall complication rates per
1000 procedures were not significantly changed throughout
the study period: iatrogenic pneumothorax (APC 2.04%,
pZ 0.31), pneumothorax requiring chest tube (APC 3.19%,
p Z 0.31), procedure related hemorrhage (APC 2.33%,
p Z 0.23).
Factors associated with complications
Table 2 shows characteristics associated with iatrogenic
pneumothorax and procedure-related hemorrhage in
univariate and multivariate logistic regression analysis.Figure 2 Age-adjusted rates of utilization of transbronchial
biopsy and other bronchoscopic procedures in Florida from
2000 to 2009.Chronic obstructive pulmonary disease (COPD) and female
gender were significantly associated with higher risk of
iatrogenic pneumothorax in multivariate analysis. Kidney
failure, cirrhosis, age and female gender were significantly
associated with increased risk of procedure-related
hemorrhage. Lung transplantation was significantly associ-
ated with lower risk for both iatrogenic pneumothorax and
procedure-related hemorrhage.Discussion
In this study we demonstrate that utilization of trans-
bronchial lung biopsy in Florida decreased by 25% from 2000
to 2009 (p < 0.0001). This decrease occurred despite
stability in the annual rate of bronchoscopy and cannot be
explained by a concomitant increase in the rate of
competing minimally invasive lung biopsy procedures such
as video-assisted thoracoscopic surgery. We did identify an
increase in the annual rate of other bronchoscopic biopsy
techniques, which raises the possibility that bronchosco-
pists are increasingly favoring these procedures over
transbronchial biopsy. Along these lines, another possibility
for decreasing utilization of transbronchial lung biopsy is
supplantation by newer bronchoscopic techniques such as
endobronchial ultrasound and electromagnetic navigational
bronchoscopy. However, because these techniques do not
have dedicated ICD-9-CM procedure codes, we were unable
to assess their use. Although no studies have previously
addressed the utilization of transbronchial biopsy, the
stable rate of fiberoptic bronchoscopy observed contrasts
with the only previous study assessing utilization of bron-
choscopy, a single center study that showed decreasing use
of bronchoscopy in the late 1990s.8
The major advantage to using comprehensive state
administrative databases for analysis of trends of proce-
dure utilization is the ability to capture nearly all proce-
dures performed in a population-based sample. A number
of disadvantages, however, exist. It is likely that our esti-
mate of the annual rate of transbronchial biopsy underes-
timates the actual rate. Using ICD-9-CM codes,
transbronchial lung biopsy must be coded in addition to
flexible or rigid bronchoscopy. Particularly in inpatients, it
is possible that coding for a minor procedure such as
transbronchial lung biopsy might be omitted. We attempted
Table 2 Risk factors for complications associated with transbronchial biopsy.
Unadjusteda odds
ratio (95% CI), p
Adjustedb odds ratio (95% CI), p
Iatrogenic pneumothorax
COPD 1.54 (1.34e1.78), <0.0001 1.51 (1.31e1.75), <0.0001
Age (per 10 years) 1.05 (1.01e1.11), 0.03 NS
Hospital yearly procedure
volume (per 100 TBBX)
0.93 (0.87e1.00), 0.04 NS
Lung transplant 0.37 (0.24e0.56), <0.0001 0.40 (0.26e0.62), <0.0001
Female gender 1.30 (1.13e1.50), 0.0002 1.32 (1.15e1.52), 0.0001
Procedure related hemorrhage
COPD 1.10 (0.90e1.33), 0.35 NS
Age (per 10 years) 1.20 (1.12e1.29), <0.0001 1.17 (1.09e1.25), <0.0001
Hospital yearly procedure
volume (per 100 TBBX)
0.92 (0.84e1.00), 0.06 NS
Lung transplant 0.31 (0.17e0.56), 0.0001 0.39 (0.21e0.72), 0.002
Female gender 1.36 (1.13e1.62), 0.001 1.40 (1.17e1.68), 0.0003
Kidney failure 2.94 (2.17e3.99), <0.0001 2.85 (2.10e3.87), <0.0001
Cirrhosis 2.40 (1.23e4.66), 0.01 2.31 (1.18e4.52), 0.01
Thrombocytopenia 1.94 (1.06e3.53), 0.03 NS
NS indicates not significant. Variables with adjusted p-values <0.05 are included in the final model.
a Derived from single-predictor logistic regression analyses.
b Derived from multivariate logistic regression models.
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combined rate of other bronchoscopic biopsies, which
would be subject to similar coding omission. The fact that
the rate of these other bronchoscopic techniques is
increasing suggests that the decrease in the annual rate of
transbronchial lung biopsy is not an artifact of coding
omission. We were also concerned that variation in the
maximal number of procedure codes available across the
study period might result in spurious estimates of proce-
dure utilization over time. The similar trends in the rates of
procedure utilization seen when the analysis was repeated
using a constant number of procedure codes available
across all study years allows us to be confident that the
substantial decrease in transbronchial biopsy utilization we
observed is real.
The majority of transbronchial biopsies were performed
in patients with a diagnosis of a pulmonary nodule, lung
cancer or parenchymal lung disease. Of note, these ICD-9-
CM codes are non-specific, as would be expected in asso-
ciation with a diagnostic procedure performed to establish
a diagnosis. Because the discharge records had no infor-
mation on pathologic results and could not be linked to
follow-up visits, we were unable to ascertain, for example,
how often transbronchial biopsy performed for “pulmonary
nodules” or “parenchymal lung disease” yielded a specific
diagnosis (e.g., sarcoidosis). While the frequency of most
associated conditions evaluated was stable throughout the
study period, the proportion of biopsies performed in
patients who had undergone lung transplantation,
increased 5-fold from 2000 to 2009. This increase corre-
sponded with a significant rise in the number of lung
transplant surgeries being performed in the state of Florida
during this time period.
One explanation for the decrease in utilization of
transbronchial biopsy may be concern for complicationsrelated to this procedure, specifically hemorrhage and/or
pneumothorax. Estimates of complications of trans-
bronchial biopsy have been highly variable. Estimates of
the risk of pneumothorax associated with transbronchial
biopsy typically range from 0 to 5%, with higher rates re-
ported in mechanically ventilated patients.2,3,9e18 The
definition of procedure-related hemorrhage is less stan-
dardized, but clinically significant hemorrhage has been
reported in 0.6e1.3% in large case series.2,3,16,17 In this
study we analyzed 82,059 transbronchial biopsies and
calculated overall rates of iatrogenic pneumothorax of
0.97% (0.55% requiring chest tube placement) and
procedure-related hemorrhage rate of 0.58%. These
complication rates were stable throughout the study
period. The complication rates calculated in this study are
lower than some previously reported estimates. In contrast
to prior studies, which were conducted primarily in single
academic centers, our study includes patients from both
large academic hospitals and community hospitals and is
more representative of the general population. It is
therefore likely that our estimates are closer to the true
complication rates within the community, where proce-
dures are typically performed in healthier individuals. It is
also likely, however, that our results underestimate the risk
of complications associated with transbronchial lung
biopsy. While in general, estimates of complications such as
iatrogenic pneumothorax and procedure-related hemor-
rhage from administrative data are considered reliable and
precise, both the procedure and the complication must be
accurately coded which may lead to events not being
captured.19e21 Reassuringly, our findings are consistent
with a recent survey of complications of bronchoscopy
procedures performed throughout Japan, which found
a 0.6% risk of pneumothorax requiring chest tube after
transbronchial biopsy, as well as a large prospective cohort
1564 M.H. Tukey, R.S. Wienerstudy addressing bleeding complications of transbronchial
biopsy in patients on aspirin which reported serious
bleeding complications in 0.7% of cases.17,18
This study is one of the first to identify specific factors
associated with complications from transbronchial biopsy.
The presence of COPD has consistently been identified as
a risk factor for pneumothorax associated with transthoracic
needle biopsy.22e28 It is therefore not surprising that COPD
was also significantly associated with risk for pneumothorax
associated with transbronchial biopsy. Similarly, cirrhosis
and uremia are well-described risks for procedure related
hemorrhage associated with bronchoscopy.1,29,30 Thrombo-
cytopenia was identified as a risk factor for procedure
related hemorrhage in univariate analysis but did not reach
statistical significance in multivariate analysis. In our series
only 1.2% of all transbronchial biopsies were performed in
patients with thrombocytopenia which may reflect both
a reluctance to perform the procedure in patients with low
platelet counts as well as failure to capture secondary
diagnoses such as thrombocytopenia in the discharge record.
In this study, female gender was also associated with
increased risk for both pneumothorax and procedure-related
hemorrhage. While studies of transthoracic needle biopsy
have not identified gender as a risk factor for pneumothorax,
one study identified female gender as a risk factor for
procedure-related hemorrhage.27 The reason for the asso-
ciation of gender with complications from transbronchial
biopsy is unclear. In contrast, lung transplantation was
associated with a decreased risk for complications associ-
ated with transbronchial biopsy. Multivariate analysis
including interaction variables suggests that this is inde-
pendent of hospital annual procedure volume. One study of
mechanically ventilated patients undergoing transbronchial
biopsy, which included 34 lung transplant patients, also
identified a decreased risk of pneumothorax in the lung
transplant population although this association did not reach
statistical significance.14 It is possible that this decreased risk
is related to individual physician experience independent of
annual hospital volume or related to the quality of the
transplanted organs (for example lack of obstructive lung
disease).31
This research, which analyzes all transbronchial lung
biopsies conducted in Florida over a decade, represents the
single largest study of transbronchial lung biopsy. Although
utilization of transbronchial lung biopsy is decreasing
relative to the use of fiberoptic bronchoscopy and other
minimally invasive lung biopsy procedures, our data suggest
that transbronchial lung biopsy is a safe procedure with
a low risk of complications for most individuals. Our findings
on characteristics associated with higher risk of complica-
tions can help physicians and patients make more informed
decisions about whether to pursue this diagnostic
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